Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products

Blood

Volumn 108, Issue 6, 2006, Pages 1841-1848

  Gross, David Alexandre ^a,b   Chappert, Pascal ^a   Leboeuf, Marylene ^a   Monteilhet, Virginie ^a   Van Wittenberghe, Laetitia ^a   Danos, Olivier ^a   Davoust, Jean ^a,b  

^a CNRS   (France)

^b GÉNÉTHON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CD4+ CD25+ T LYMPHOCYTE; CHIMERA; CLONAL ANERGY; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GRAFT REJECTION; HOST; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN TRANSPLANTATION; THYMECTOMY;

EID: 33748687375     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-011981     Document Type: Article

References (52)

1. Cossu G, Sampaolesi M. New therapies for muscular dystrophy: cautious optimism. Trends Mol Med. 2004;10:516-520.
2. Wang L, Herzog RW. AAV-mediated gene transfer for treatment of hemophilia. Curr Gene Ther. 2005;5:349-360.
3. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004;11(suppl 1):S10-S17.
4. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther. 2003;10:955-963.
5. Brown BD, Lillicrap D. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood. 2002;100:1133-1140.
6. Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 2001;4:192-200.
7. Sarukhan A, Camugli S, Gjata B, von Boehmer H, Danos O, Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol. 2001;75:269-277.
8. Sykes M. Mixed chimerism and transplant tolerance. Immunity. 2001;14:417-424.
9. Nikolic B, Takeuchi Y, Leykin I, Fudaba Y, Smith RN, Sykes M. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes. 2004;53:376-383.
10. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature. 2005;435:620-627.
11. Tian C, Bagley J, Kaye J, Iacomini J. Induction of T cell tolerance to a protein expressed in the cytoplasm through retroviral-mediated gene transfer. J Gene Med. 2003;5:359-365.
12. Andersson G, Denaro M, Johnson K, et al. Engraftment of retroviral EGFP-transduced bone marrow in mice prevents rejection of EGFP-transgenic skin grafts. Mol Ther. 2003;8:385-391.
13. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000;6:464-469.
14. Lin CY, Graca L, Cobbold SP, Waldmann H. Dominant transplantation tolerance impairs CD8+ T cell function but not expansion. Nat Immunol. 2002;3:1208-1213.
15. Waldmann H, Cobbold S. Exploiting tolerance processes in transplantation. Science. 2004;305:209-212.
16. Simpson E, Scott D, James E, et al. Minor H antigens: genes and peptides. Eur J Immunogenet. 2001;28:505-513.
17. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345-352.
18. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005;6:331-337.
19. Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest. 2004;114:1398-1403.
20. Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112:1688-1696.
21. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al. L-selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004;104:3804-3812.
22. Joffre O, Gorsse N, Romagnoli P, Hudrisier D, van Meerwijk JP. Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes. Blood. 2004;103:4216-4221.
23. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6:338-344.
24. Hori S, Haury M, Coutinho A, Demengeot J. Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in antimyelin basic protein T cell receptor transgenic mice. Proc Natl Acad Sci U S A. 2002;99:8213-8218.
25. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
26. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004;199:1467-1477.
27. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199:1455-1465.
28. Gross DA, Leboeuf M, Gjata B, Danos O, Davoust J. CD4+CD25+ regulatory T cells inhibit immune-mediated transgene rejection. Blood. 2003;102:4326-4328.
29. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol. 2002;3:1156-1162.
30. Fisson S, Darrasse-Jeze G, Litvinova E, et al. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med. 2003;198:737-746.
31. Andersson G, Illigens BM, Johnson KW, et al. Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood. 2003;101:4305-4312.
32. Sena J, Wachtel SS, Murphy G. A comparison of the survival of H-Y incompatible ear, tail, and body skin grafts. Transplantation. 1976;21:412-416.
33. Mathieson BJ, Flaherty L, Bennett D, Boyse EA. Differences in the rejection of trunk skin and tail skin allografts involving weak histocompatibility loci. Transplantation. 1975;19:525-527.
34. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196:401-406.
35. Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rotzschke O, Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood. 2005;105:2877-2886.
36. Jordan MS, Boesteanu A, Reed AJ, et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol. 2001;2:301-306.
37. Apostolou I, Sarukhan A, Klein L, von Boehmer H. Origin of regulatory T cells with known specificity for antigen. Nat Immunol. 2002;3:756-763.
38. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol. 2001;167:1137-1140.
39. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2005;102:419-424.
40. Bagley J, Bracy JL, Tian C, Kang ES, Iacomini J. Establishing immunological tolerance through the induction of molecular chimerism. Front Biosci. 2002;7:d1331-d1337.
41. Tian C, Bagley J, Cretin N, Seth N, Wucherpfennig KW, Iacomini J. Prevention of type 1 diabetes by gene therapy. J Clin Invest. 2004;114:969-978.
42. Quesenberry PJ, Ramshaw H, Crittenden RB, et al. Engraftment of normal murine marrow into nonmyeloablated host mice. Blood Cells. 1994;20:348-350.
43. Rao SS, Peters SO, Crittenden RB, Stewart FM, Ramshaw HS, Quesenberry PJ. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol. 1997;25:114-121.
44. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol. 2003;3:147-158.
45. June CH, Blazar BR. Clinical application of expanded CD4(+)25(+) cells. Semin Immunol. 2006;18:78-88.
46. Masteller EL, Tang Q, Bluestone JA. Antigen-specific regulatory T cells - ex vivo expansion and therapeutic potential. Semin Immunol. 2006;18:103-110.
47. Fisson S, Djelti F, Trenado A, et al. Therapeutic potential of self-antigen-specific CD4(+)CD25(+) regulatory T cells selected in vitro from a polyclonal repertoire. Eur J Immunol. 2006;36:817-827.
48. Jaeckel E, von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes. 2005;54:306-310.
49. Chai JG, Xue SA, Coe D, et al. Regulatory T cells, derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation. 2005;79:1310-1316.
50. Allan SE, Passerini L, Bacchetta R, et al. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest. 2005;115:3276-3284.
51. Chen TC, Waldmann H, Fairchild PJ. Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. J Clin Invest. 2004;113:1754-1762.
52. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005;6:1219-1227.